7

Equity | India · Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18 Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24 ... Housing Development Finance Corporation Ltd

  • Upload
    others

  • View
    5

  • Download
    1

Embed Size (px)

Citation preview

Page 1: Equity | India · Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18 Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24 ... Housing Development Finance Corporation Ltd
Page 2: Equity | India · Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18 Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24 ... Housing Development Finance Corporation Ltd

Equity | India

Diwali Picks 2018

October 31, 2018

Rohit Chavan +91-22- 6614 2694 | [email protected] 1

The System:

The Table 1 below depicts the percentage returns that each of the sectoral indices have given over two different

time frames. One is roughly around a year’s time (Between Last Diwali on 19.10.2017 to date of preparation of this

report 25.10.2018). The other is from the date the NIFTY hit an all-time HIGH (28.8.2018) to date of preparation

of this report 25.10.2018. The date of 28.8.2018 assumes significance as it is the time when the investor

confidence was the highest. On each of these percentages we have assigned the RANKS. A summation of these two

RANKINGS put together gives us the “Total Rank”.

The Hypothesis:

The sectors that have the TOP ranks have remained quiet stable even in uncertain times, after having

outperformed on the way UP. Hence one would be into much SAFER sectors being into the scrips listed within the

purview. As a corollary, RISK may only be taken on scrips within the sectors that have outperformed on the double

counts.

The Observations:

The benchmark NIFTY (marked in GREEN) stands on the 11th ranking on the overall scenario. The next on

breadth, the NIFTY 100 stands on the 13th rank. The broader indices like NIFTY 200 & NIFTY 500 stand

much LOWER on the ranks. This is an indication that on the way UP as well as the way DOWN, the safety

remains with large-caps (By the new nomenclature norms, the top 100 companies by market capitalization

are marked as large caps; the next 101 to 250 are mid-caps while the remainder are all small-caps).

Further to substantiate the turmoil in the smallcaps & midcaps, the two indices that encompass them stand

on the second last & fifth last positions. This also puts the emphasis on the SAFETY angle.

The NIFTY QUALITY 30 has scored equal marks as the benchmark NIFTY itself, indicating to the need for

QUALITY in the portfolio. The recent FALL in stock markets has “Taught us Quality & nothing but QUALITY”.

Sectorally, the bets still remain with the defensives with the likes of NIFTY IT, NIFTY FMCG, NIFTY PHARMA

forming the list of sectors that have outperformed the benchmark on the rankings part.

Sectorally, although the FINANCIAL SERVICES sector has been going through upheavals in recent time, has

remained in a SWEET spot.

The Inferences:

The stock selection in current scenario calls for a more “STRATEGIC” approach rather than just the simple

“LOGISTIC” approach.

The risks thus should be taken in sectors wherein there is a clear OUTPERFORMANCE.

Page 3: Equity | India · Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18 Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24 ... Housing Development Finance Corporation Ltd

Equity | India

Diwali Picks 2018 October 31, 2018

BUY

Diwali Picks 2018 2

The Actionables:

Based on the above hypothesis, we have short listed a list of 5 stocks for the new SAMVAT 2075,that would embark

on the pillars of SAFETY & OUTPERFORMANCE. The list includes the bellwethers like HDFC Ltd and KOTAKBANK on

the largecap section, EXIDEIND within the midcap section and TATAELXSI within the smallcap section. Diwali is a

festival of lights, and hence we have also included the CRACKERS in the form of FINEORGANICS.

Table 1: Ranking System For Sectoral, Thematic & Market Capitalization Based Indices

Ticker From Val

Date(19/10/2017) To Val

Date(25/10/2018) % return Rank I

From Val date(28/08/2018)

% return Rank II Total Rank

NIFTYIT 10890.75 14070.8 29.2 1 15583.05 -9.7 5 6

Nifty Serv Sector 13108.85 13765.05 5.01 4 15683.45 -12.23 9 13

BANKNIFTY 24009.75 24817.45 3.36 7 28269.65 -12.21 8 15

Nifty FMCG 25580 28413.6 11.08 2 32494.35 -12.56 13 15

Nifty Fin Service 9934.75 10341.7 4.1 5 11796.95 -12.34 11 16

Nifty50 Value 20 4360.15 4832.7 10.84 3 5547.3 -12.88 14 17

Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18

Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24

Nifty Div Opps 50 2553 2462.8 -3.53 19 2779.7 -11.4 6 25

Nifty Metal 3819.9 3306.8 -13.43 28 3597.2 -8.07 1 29

NIFTY 10146.55 10124.9 -0.21 13 11738.5 -13.75 17 30

NIFTY100 Qualty30 2395.5 2414.1 0.78 8 2845.6 -15.16 22 30

Nifty 100 10517.3 10307.7 -1.99 14 12028.3 -14.3 18 32

Nifty CPSE 2585.9 2152.95 -16.74 30 2359.1 -8.74 3 33

NIFTY100 EQL Wgt

12105.85

10 14370.85 -15.76 24 34

NIFTYPSE 4199.2 3359.95 -19.99 33 3677.25 -8.63 2 35

Nifty 200 5511 5327.8 -3.32 17 6244.4 -14.68 20 37

Nifty Mid Liq 15 3962.95 3693.4 -6.8 23 4240.4 -12.9 15 38

NIFTYINFRA 3405.65 2851.65 -16.27 29 3251.75 -12.3 10 39

Nifty GrowSect 15 6206.4 6071.6 -2.17 15 7309.75 -16.94 26 41

Nifty 500 8937.65 8473.5 -5.19 21 9985.9 -15.15 21 42

NIFTY Alpha 50

11668.65

9 14795.9 -21.14 33 42

Nifty Energy 13979.95 13491.35 -3.5 18 16241.65 -16.93 25 43

Nifty Consumption 4596.1 4476.25 -2.61 16 5390.6 -16.96 27 43

Nifty Commodities 3972.05 3301.25 -16.89 31 3826.5 -13.73 16 47

Nifty Midcap 50 4883.05 4462.35 -8.62 24 5272.55 -15.37 23 47

Nifty MNC 13422.45 12534.85 -6.61 22 15124.95 -17.12 28 50

Nifty Next 50 28588.3 25335.8 -11.38 25 30768.1 -17.66 31 56

NIFTY MIDCAP 100 18789.9 16276.05 -13.38 27 19718.4 -17.46 30 57

Nifty PSU Bank 2942.7 2582.25 -12.25 26 3234 -20.15 32 58

Nifty Media 2943.4 2367.05 -19.58 32 2865.25 -17.39 29 61

Nifty Auto 11107.7 8580.95 -22.75 34 11044.15 -22.3 34 68

NIFTY SMLCAP 100 8068 5784.2 -28.31 36 7597.7 -23.87 35 71

Nifty Realty 287.25 206 -28.29 35 271.2 -24.04 36 71

Page 4: Equity | India · Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18 Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24 ... Housing Development Finance Corporation Ltd

Equity | India

Diwali Picks 2018 October 31, 2018

BUY

Diwali Picks 2018 3

Our Recommendations For Diwali 2018 (Samvat 2075)

Sr No Name Sector Reco Price Target Price Upside % Time Frame

1

Housing Development Finance Corporation Ltd. (HDFC Ltd.)

Finance 1,694.4 2,063 21.7% 1 Year

2

Kotak Mahindra Bank Ltd. (KOTAKBANK)

Bank 1,185.8 1420.0 19.7% 1 Year

3 Exide Industries Ltd.

(EXIDEIND)

Automobile &

Ancillaries 255.5 305.0 19.4% 1 Year

4 Tata Elxsi Ltd.

(TATAELXSI) IT 955.3 1,144.0 19.8% 1 Year

5 Fine Organic Industries

Ltd. (FINEORG) Chemicals 1,039.7 1,325.0 27.5% 1 Year

** CMP updated as on 25th October 2018

Gist of The Recommendations

HDFC Ltd: Higher Growth will drive the company for longer term:

Housing Development

Finance Corporation Ltd. BUY CMP(`):1,694.4 Target (`):2,063 Upside: 21.7%

Given its market leadership position, HDFC is envisaged to be a key beneficiary of

government’s/regulator’s thrust on the housing sector, lending growth visibility and India’s mortgage

market is attractive given favorable demographics. Low mortgage penetration at 10% of GDP is a positive

for company.

HDFC is taking a conservative approach and its benign asset quality is not only the function of its operating

segment, but also reflects its strong know-how (particularly in non-individual loan segment). As such, we

do not expect any major deviation in asset quality.

Best‐in‐class cost ratios and adequate provisioning buffer will ensure steady operational performance. High

value discovery via listing of HDFC Mutual Fund is a positive trigger.

Page 5: Equity | India · Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18 Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24 ... Housing Development Finance Corporation Ltd

Equity | India

Diwali Picks 2018 October 31, 2018

BUY

Diwali Picks 2018 4

Kotak Mahindra Bank Ltd: Banking on Prudent Business:

Kotak Mahindra Bank

Ltd. BUY CMP(`):1,185.8 Target (`):1420.0 Upside: 19.7%

Kotak Mahindra Bank offers financial products across the board – credit, deposits, wealth management,

broking, life insurance, general insurance, investment banking, asset management, auto loans. With such a

vast array of products in its portfolio, there are large synergistic opportunities to cross-sell across the

group.

811 continues to be the bank’s strategy to acquire customers. Strategies at each of the subsidiaries too will

unfold gradually over time unlocking huge value for investors.

As a group, Kotak has enough management bandwidth and a highly qualified and skilled bench to execute

its evolution and ride the Indian financialization wave.

Exide Ltd: Adapting to the Growth Potential:

Exide Industries Ltd. BUY CMP(`):255.5 Target (`):305.0 Upside: 19.4%

Aggressive Expansion Plan: Company has done Rs. 1400 crore Capex to introduce high performance and

more durable automotive batteries in India. Out of total capex half of the amount has been invested in its

Haldia plant for producing batteries with a "punch grid technology" and balance Rs. 700 crore was invested

in Fy 2017-18 for automating some key functions through robotic technology to meet Global standards.

There are more than 1500 Exide care exclusive outlets ensuring best-in-class customer experience offered

with complete auto power solutions through wide range of products and is expanding.

Launch of Zero maintenance battery product line: Company has an ongoing technical assistance and

collaboration agreement with ‘Furukawa Battery Company Limited, Japan” for various automotive

applications which will improve efficiency and reduce costs.

The coming wave of electric vehicle is a big opportunity to organized player like Exide and Exide is working

very proactively to capture this market.

Page 6: Equity | India · Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18 Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24 ... Housing Development Finance Corporation Ltd

Equity | India

Diwali Picks 2018 October 31, 2018

BUY

Diwali Picks 2018 5

Tata Elxsi Ltd: Growing with Technology:

Tata Elxsi Ltd. BUY CMP(`):955.3 Target (`): 1144.0 Upside: 19.8%

Going forward, given substantial growth being witnessed in digital portfolios of most IT firms, along with

investments into avenues like autonomous vehicles, AR/VR experience and automotive electronics, we

believe TEL will be one of the key beneficiaries of the same, given its presence in these emerging

businesses.

We expect its diversified portfolio including automotive, broadcast, medical and design expertise to enable

TEL to leverage these investments disproportionately. We would watch growth from IP-led engagements in

future given scope for margin expansion, with the Autonomic platform a critical driver.

We believe TEL is a good long-term investment bet, given its presence across fast-growing solutions, niche

area of operations, design expertise, marquee client base, pricing power, operating leverage, healthy cash

flow, and returns on capital and strong earnings growth.

Fine Organics Industries Ltd: Unique Products with Growing Scale:

Fine Organics Ind. Ltd. BUY CMP(`):1,039.7 Target (`):1,325.0 Upside: 27.5%

Company is the largest manufacture of oleo chemical-based additive in India and a strong global player.

These specialty chemical based products are widely used in Food, Plastics, Cosmetics, Paints, Ink, Coatings

and other specialty application in various industries.

Currently, the company is having a strong consumer based operations in 69 countries with ~631 direct

customers, ~127 distributors. It has three production facilities in (Ambernath, Badlapur and Dombivili)

Maharashtra with the combines installed capacity of 64,300 TPA and also having JV with (Olefin Organics, a

partnership firm and a promoter group entity) to manufacture the products with installed capacity of ~5000

TPA.

Page 7: Equity | India · Nifty Pvt Bank 13557.4 14073.8 3.81 6 16088.9 -12.52 12 18 Nifty Pharma 9593.5 9142.7 -4.7 20 10050.1 -9.03 4 24 ... Housing Development Finance Corporation Ltd

Equity | India

Diwali Picks 2018 October 31, 2018

BUY

Diwali Picks 2018 6

Research Team:

Name Designation Email Id Contact

Pushkaraj Kanitkar AVP - Technical Research [email protected] 022 - 6614 2686

Rohit Chavan Analyst - Fundamental Research [email protected] 022 - 6614 2694

We, Research Analyst of GEPL Capital, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject

issuer(s) or securities. We, also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or

view(s) in this report.

Disclosure :-

This document has been prepared by Research Department of GEPL Capital Pvt. Ltd. (hereinafter referred to as GEPL) and this report is for personal information of the selected

recipient/s and does not construe to be any investment, recommendation, prospectus, offering circular or legal or taxation advice to you. This research report does not consti-tute

an offer, invitation or inducement to invest in securities or other investments and GEPL is not soliciting any action based upon it. This report is not for public distribution and has

been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not consti-tute a personal

recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this

material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments

referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past perfor-mance is not a guide for future

performance, future returns are not guaranteed and a loss of original capital may occur. GEPL makes no representation or warranty, express or implied, as to, and does not accept

any responsibility or liability or obligation with respect to, the fairness, accuracy, completeness or correctness of any information or update information or opinions contained

herein.

All investments including Future and Options are involving risks and investors should exercise prudence in making their investment decisions. The report should not be regard-ed by

the recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to

opinions expressed by other business areas or GEPL as a result of using different assumptions and criteria. Foreign currency rates of exchange may adversely affect the value, price

or income of any security or related instrument mentioned in this report.

The information contained in this report has been obtained from sources that are considered to be reliable. However, GEPL has not independently verified the accuracy or

completeness of the same. Neither GEPL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and

opinion given, made available or expressed herein or for any omission therein.

GEPL and its affiliates and/or their officers, directors and employees may have similar position in any securities mentioned in this document (or in any related investment) and may

from time to time add to or dispose of any such securities (or investment. GEPL specifically prohibits the redistribution of this material in whole or in part without the written

permission of GEPL and GEPL accepts no liability whatsoever for the actions of third parties in this regard. GEPL or its director or its research analysts or its associates or his relatives

and/or its affiliates and/or employees do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately

preceding the date of publication of the research report.

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are

contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommenda-tions

expressed herein.

Disclaimers in respect of jurisdiction:

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdic-tion

where such Distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject GEPL its affiliates to any registration or licensing

requirement within such jurisdiction. If this report is inadvertently send or has reached any individual the same may be ignored and brought to the attention of the sender. This

document may not be reproduced, distributed or published for any purposes without prior written approval of GEPL.

Analyst Certification:

The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues. Compensation of our Research Analysts is not based on

any specific merchant banking, investment banking or brokerage service transactions. Research Analysts of this report have not received any compensation from the companies

mentioned in the report in the preceding twelve months. GEPL Capital Private Limited is a SEBI registered Research Analyst entity bearing SEBI Reg. No. “INH000000081” under SEBI

(Research Analysts) Regulations, 2014.

Reg. Office : D-21 Dhanraj Mahal, CSM Marg, Colaba, Mumbai 400 001 | Contact No +91 22 66182400 | CIN No.: U67120MH1997PTC11094

SEBI Reg.No. NSE/BSE/CURRENCY/F&O - INZ000168137

For more information visit us at: www.geplcapital.com | For research related queries email at [email protected]